Anti-Inflammatory or Anti-Rheumatic Drugs
(Sprache: Englisch)
Our goal for this book is to examine the contemporary therapy of rheumatoid arthritis (RA) from the increasingly important perspective of impact upon quality of life, costs and long-term health outcomes. For too long the focus has been on short term,...
Leider schon ausverkauft
versandkostenfrei
Buch (Gebunden)
175.99 €
- Lastschrift, Kreditkarte, Paypal, Rechnung
- Kostenlose Rücksendung
- Ratenzahlung möglich
Produktdetails
Produktinformationen zu „Anti-Inflammatory or Anti-Rheumatic Drugs “
Klappentext zu „Anti-Inflammatory or Anti-Rheumatic Drugs “
Our goal for this book is to examine the contemporary therapy of rheumatoid arthritis (RA) from the increasingly important perspective of impact upon quality of life, costs and long-term health outcomes. For too long the focus has been on short term, symptomatic, and surrogate indicator outcomes. Yet RA is a life-long disor der with the majority of impact on an individual patient many years following onset. Further, even in the short-term, researchers and rheumatologists have tended to emphasize measurements of disease activity such as joint counts, ESR and physi cian's opinion as to the amount of disease activity present. It is only relatively recently that measures of structural damage, quality of life and impact on broad domains of health have been given increasing emphasis. Also, the significance of early treatment of RA in order to optimise long-term outcomes has a relatively short history [1]. We have been focussed on the disease processes as surrogates for long term outcomes. Until the short-term process measures are validated as surrogates of long-term effects we should also turn our attention to outcomes of disease and the impact of our management on those outcomes [2). Inour view, this book is especially timely. We are at the dawn of a revolution in the management of RA and other complex immunological inflammatory disorders because their molecular, genetic and environmental mechanisms are being unrav elled. Inthe process, we are revealing a substantial number of novel and significant targets for pharmacotherapy.
Inhaltsverzeichnis zu „Anti-Inflammatory or Anti-Rheumatic Drugs “
G.G. Graham: Medicinal chemistry of the disease modifying anti-rheumatic drugs- M.E. Suarez-Almazor: Targeting DMARD therapy
- A. Maetzel and D.H. Solomon: Pharmacoeconomic properties of disease-modifying anti-rheumatic drugs
- E.C. Keystone and B. Haraoui: Future molecular targets
- B. Bothwell and D.E. Furst: Hydroxychloroquine
- C. J. Haagsma: Sulfasalazine
- R. Rau: Gold
- D. Kane and B. Bresnihan: Azathioprine
-K. Pile: Methotrexate
- A. Hoi and G. Littlejohn: Leflunomide
- A.W.R. van Kuijk and B. A.C. Dijkmans: Cyclosporine
- K. Bird and J.R. O’Dell: Tetracyclines
- J.R. Kirwan and M.G. Perry: Systemic glucocorticoids in rheumatoid arthritis
- Z. Tutuncu and A. Kavanaugh: TNF inhibitors
- B. Bresnihan: Anakinra in rheumatoid arthritis. - E. Choy and H.E. Paulus: Combination therapy
- A. Tyndall and J.M. van Laar: Hematopoietic stem cell transplantation for the treatment of severe autoimmune diseases
Bibliographische Angaben
- 2004, 2005, 343 Seiten, 300 Abbildungen, Maße: 17,3 x 24,6 cm, Gebunden, Englisch
- Herausgegeben: R. O. Day, D. E. Furst, P. L. V. Riel
- Verlag: Birkhäuser Basel
- ISBN-10: 3764365951
- ISBN-13: 9783764365950
- Erscheinungsdatum: 21.12.2004
Sprache:
Englisch
Kommentar zu "Anti-Inflammatory or Anti-Rheumatic Drugs"
Schreiben Sie einen Kommentar zu "Anti-Inflammatory or Anti-Rheumatic Drugs".
Kommentar verfassen